Schoenfeld P, Paul S
Retatrutide is a Phase 3 investigational compound not yet approved by any regulatory agency as of June 2026
This ingredient helps soothe redness and irritation, especially when combined with antioxidants and hydrating agents
You should not take Wegovy or Zepbound if you: Have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) Have ever had a serious allergic reaction to semaglutide, tirzepatide, or any ingredient in these medications Are pregnant, breastfeeding, or trying to conceive
Clean the rubber stopper of the vial with an alcohol prep pad before inserting the needle
Educational resources In addition to the documents linked above, WADA has provided, or will provide, a number of educational resources as part of its Code Implementation Support Program (CISP), which can be accessed on the Agencys Anti-Doping Education and Learning Platform (ADEL)